The TAM (Tyro3, AXL, MerTK) family of RTKs has oncogenic potential and both the expression of MerTK and AXL can increase in EGFRM+ NSCLC treated with EGFR-TKIs and induce acquired resistance to these drugs [227]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.